Ampersand Biomedicines
Changrui Xing is a skilled scientist with extensive experience in antibody engineering, protein expression, purification, and characterization. Currently serving as a Scientist II at Ampersand Biomedicines, Changrui focuses on antibody engineering, analytics, and discovery. Previously, at Memorial Sloan Kettering Cancer Center, Changrui worked as a Research Fellow, where responsibilities included developing functional assays and utilizing cryo-electron microscopy for structure elucidation. During a Ph.D. tenure at the University of Pittsburgh, significant contributions included discovering the first cryo-EM structure of the human cannabinoid receptor CB2-Gi complex and developing protocols for protein studies. Earlier roles included research positions at Fudan University and internships at Roche and the Shanghai Institute for Food and Drug Control, contributing to drug development and quality control measures. Changrui holds a Doctor of Philosophy in Structural Biology and Pharmaceutical Sciences from the University of Pittsburgh and a Bachelor of Science in Pharmaceutical Sciences from Fudan University.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.